Quarterly report pursuant to Section 13 or 15(d)

Note 16 - Segments - Segment Information (Details)

v3.7.0.1
Note 16 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Other income, excluding equity in loss of R-NAV, LLC (4) [1]   $ 1,427,078   $ 2,515,902  
Equity in loss of R-NAV, LLC (2,920) (15,159)  
Other income 40,848 1,424,158 (1,130,261) 2,500,743  
Income tax benefit (expense) 1,631,234 0 3,085,406  
Net income (loss) from continuing operations (3,151,777) (816,517) (6,016,392) (3,498,333)  
Loss from discontinued operations, net of tax (82,376) (5,864,790) (338,237) (6,869,223)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax (1,953,378) 86,748,123  
Net income (5,187,531) (6,681,307) 80,393,494 (10,367,556)  
Total assets, net of depreciation and amortization 25,902,215   25,902,215   $ 12,461,676
Capital expenditures 8,170 1,847 8,170 1,847  
Tc 99m tilmanocept sales revenue 4,399 13,199  
Tc 99m tilmanocept license revenue 100,000 245,950 100,000 500,000  
Grant and other revenue 511,599 916,811 1,091,629 1,602,446  
Revenues 611,599 1,167,160 1,191,629 2,115,645  
Cost of goods sold, excluding depreciation and amortization 807 2,296  
Research and development expenses, excluding depreciation and amortization 1,185,874 2,019,211 1,891,148 4,091,482  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [2] 4,179,045 1,293,633 7,124,689 3,851,793  
Depreciation, Depletion and Amortization, Nonproduction [3] 70,539 94,184 147,329 169,150  
Income (loss) from operations (3) [4] (4,823,859) (2,240,675) (7,971,537) (5,999,076)  
UNITED STATES          
Total assets, net of depreciation and amortization 25,801,110 8,360,199 25,801,110 8,360,199  
Tc 99m tilmanocept sales revenue  
Non-US [Member]          
Total assets, net of depreciation and amortization 101,105 321,950 101,105 321,950  
Tc 99m tilmanocept sales revenue 4,399 13,199  
Diagnostics Segment [Member]          
Other income, excluding equity in loss of R-NAV, LLC (4) [1]      
Equity in loss of R-NAV, LLC      
Other income      
Income tax benefit (expense) 201,125   146,296    
Net income (loss) from continuing operations (388,601) (792,984) (285,270) (1,676,459)  
Loss from discontinued operations, net of tax (82,376) (5,864,790) (338,237) (6,869,223)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax (1,953,378)   86,748,123    
Net income (2,424,355) (6,657,774) 86,124,616 (8,545,682)  
Capital expenditures  
Tc 99m tilmanocept license revenue 100,000 245,950 100,000 500,000  
Grant and other revenue 418,375 865,359 989,737 1,550,994  
Revenues 518,375 1,115,708 1,089,737 2,064,193  
Cost of goods sold, excluding depreciation and amortization 807 2,296  
Research and development expenses, excluding depreciation and amortization 1,108,101 1,907,885 1,521,303 3,738,356  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [2]  
Depreciation, Depletion and Amortization, Nonproduction [3]  
Income (loss) from operations (3) [4] (589,726) (792,984) (431,566) (1,676,459)  
Diagnostics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 16,373,919 4,774,933 16,373,919 4,774,933  
Tc 99m tilmanocept sales revenue  
Diagnostics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 98,806 321,359 98,806 321,359  
Tc 99m tilmanocept sales revenue 4,399 13,199  
Therapeutics Segment [Member]          
Other income, excluding equity in loss of R-NAV, LLC (4) [1]      
Equity in loss of R-NAV, LLC      
Other income      
Income tax benefit (expense) (4,089)   92,861    
Net income (loss) from continuing operations 7,900 (64,304) (181,075) (305,506)  
Loss from discontinued operations, net of tax  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax      
Net income 7,900 (64,304) (181,075) (305,506)  
Capital expenditures  
Tc 99m tilmanocept license revenue  
Grant and other revenue 93,224 51,452 101,892 51,452  
Revenues 93,224 51,452 101,892 51,452  
Cost of goods sold, excluding depreciation and amortization  
Research and development expenses, excluding depreciation and amortization 77,773 111,326 369,845 353,126  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [2] 3,462 4,430 5,983 3,832  
Depreciation, Depletion and Amortization, Nonproduction [3]  
Income (loss) from operations (3) [4] 11,989 (64,304) (273,936) (305,506)  
Therapeutics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 16,002 36,841 16,002 36,841  
Tc 99m tilmanocept sales revenue  
Therapeutics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization  
Tc 99m tilmanocept sales revenue  
Corporate Segment [Member]          
Other income, excluding equity in loss of R-NAV, LLC (4) [1]   1,427,078   2,515,902  
Equity in loss of R-NAV, LLC   (2,920)   (15,159)  
Other income 40,848   (1,130,261)    
Income tax benefit (expense) 1,434,198   2,846,249    
Net income (loss) from continuing operations (2,771,076) 40,771 (5,550,047) (1,516,368)  
Loss from discontinued operations, net of tax  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax      
Net income (2,771,076) 40,771 (5,550,047) (1,516,368)  
Capital expenditures 8,170 1,847 8,170 1,847  
Tc 99m tilmanocept license revenue  
Grant and other revenue  
Revenues  
Cost of goods sold, excluding depreciation and amortization  
Research and development expenses, excluding depreciation and amortization  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [2] 4,175,583 1,289,203 7,118,706 3,847,961  
Depreciation, Depletion and Amortization, Nonproduction [3] 70,539 94,184 147,329 169,150  
Income (loss) from operations (3) [4] (4,246,122) (1,383,387) (7,266,035) (4,017,111)  
Corporate Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 9,411,189 3,548,425 9,411,189 3,548,425  
Tc 99m tilmanocept sales revenue  
Corporate Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 2,299 591 2,299 591  
Tc 99m tilmanocept sales revenue  
[1] Amounts consist primarily of changes in fair value of financial instruments and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
[2] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[3] Depreciation and amortization is reflected in selling, general and administrative expenses ($70,539 and $94,184 for the three-month periods ended June 30, 2017 and 2016 and $147,329 and $169,150 for the six-month periods ended June 30, 2017 and 2016, respectively).
[4] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.